1. Scrip
  2. >>Business

J&J Expands Ketamine Case With Spravato Monotherapy Indication

 
• By Joseph Haas

On the US market since 2019 for treatment-resistant depression in tandem with oral antidepressants, J&J’s new indication allows for more flexibility.

J&J obtained a third US indication for treatment-resistant depression drug Spravato • Source: Scrip

With Spravato (esketamine) showing signs of solid growth during its fifth year on the market in 2024, Johnson & Johnson got another sign of confidence for the treatment-resistant depression drug on 21 January, with the US Food and Drug Administration approving a third indication of monotherapy in TRD patients.

Key Takeaways
  • Johnson & Johnson obtained a third US indication for Spravato, this time for monotherapy in treatment-resistant depression.
  • The nasal-spray formulation of ketamine...

“This approval gives patients and healthcare professionals the freedom to further personalize treatment plans and options to determine the best way to incorporate Spravato into their care – either alone...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Genentech, Orionis Stick Together In Second Molecular Glue Deal

 
• By Alaric DeArment

Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts

 
• By Mandy Jackson

Restructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

More from Therapy Areas

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.